DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

63 Downloads (Pure)

Resumé

Phenytoin is a first-generation antiepileptic drug, which is used in the treatment of focal seizures and as standard of care for patients with benzodiazepine-refractory status epilepticus. Elimination of phenytoin occurs primarily via CYP enzyme–dependent hepatic clearance. The first step is the para-hydroxylation from active phenytoin to inactive hydroxy-phenytoin, which is dependent on CYP2C9 and, to a lesser extent, on CYP2C19. A considerable disparity in CYP2C9 alleles exists, and the frequency varies among different ancestry groups, the CYP2C9*3 allele being less frequent in Caucasians and more frequent in Asian populations.1,2 Homozygosity for the CYP2C9*3 allele leads to a significant reduction in enzyme activity, resulting in increased plasma levels of phenytoin.3
OriginalsprogEngelsk
Artikelnummere272
TidsskriftNeurology: Genetics
Vol/bind4
Udgave nummer5
Antal sider3
ISSN2376-7839
DOI
StatusUdgivet - 1. okt. 2018

Citer dette

@article{3940403b008942c2af971da9ed3daa8c,
title = "DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity",
abstract = "Phenytoin is a first-generation antiepileptic drug, which is used in the treatment of focal seizures and as standard of care for patients with benzodiazepine-refractory status epilepticus. Elimination of phenytoin occurs primarily via CYP enzyme–dependent hepatic clearance. The first step is the para-hydroxylation from active phenytoin to inactive hydroxy-phenytoin, which is dependent on CYP2C9 and, to a lesser extent, on CYP2C19. A considerable disparity in CYP2C9 alleles exists, and the frequency varies among different ancestry groups, the CYP2C9*3 allele being less frequent in Caucasians and more frequent in Asian populations.1,2 Homozygosity for the CYP2C9*3 allele leads to a significant reduction in enzyme activity, resulting in increased plasma levels of phenytoin.3",
author = "Nissen, {Mette S.} and Beier, {Christoph P.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1212/NXG.0000000000000272",
language = "English",
volume = "4",
journal = "Neurology: Genetics",
issn = "2376-7839",
publisher = "Wolters Kluwer Health",
number = "5",

}

DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity. / Nissen, Mette S.; Beier, Christoph P.

I: Neurology: Genetics, Bind 4, Nr. 5, e272, 01.10.2018.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity

AU - Nissen, Mette S.

AU - Beier, Christoph P.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Phenytoin is a first-generation antiepileptic drug, which is used in the treatment of focal seizures and as standard of care for patients with benzodiazepine-refractory status epilepticus. Elimination of phenytoin occurs primarily via CYP enzyme–dependent hepatic clearance. The first step is the para-hydroxylation from active phenytoin to inactive hydroxy-phenytoin, which is dependent on CYP2C9 and, to a lesser extent, on CYP2C19. A considerable disparity in CYP2C9 alleles exists, and the frequency varies among different ancestry groups, the CYP2C9*3 allele being less frequent in Caucasians and more frequent in Asian populations.1,2 Homozygosity for the CYP2C9*3 allele leads to a significant reduction in enzyme activity, resulting in increased plasma levels of phenytoin.3

AB - Phenytoin is a first-generation antiepileptic drug, which is used in the treatment of focal seizures and as standard of care for patients with benzodiazepine-refractory status epilepticus. Elimination of phenytoin occurs primarily via CYP enzyme–dependent hepatic clearance. The first step is the para-hydroxylation from active phenytoin to inactive hydroxy-phenytoin, which is dependent on CYP2C9 and, to a lesser extent, on CYP2C19. A considerable disparity in CYP2C9 alleles exists, and the frequency varies among different ancestry groups, the CYP2C9*3 allele being less frequent in Caucasians and more frequent in Asian populations.1,2 Homozygosity for the CYP2C9*3 allele leads to a significant reduction in enzyme activity, resulting in increased plasma levels of phenytoin.3

U2 - 10.1212/NXG.0000000000000272

DO - 10.1212/NXG.0000000000000272

M3 - Journal article

VL - 4

JO - Neurology: Genetics

JF - Neurology: Genetics

SN - 2376-7839

IS - 5

M1 - e272

ER -